Impaired Glucose Metabolism Among Those with and Without Diagnosed Diabetes and Mortality: a Cohort Study Using Health Survey for England Data

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Mar 19

PMID 25785731

Citations 10

Authors

Vanessa L Z Gordon-Dseagu

Jennifer S Mindell

Andrew Steptoe

Alison Moody

Jane Wardle

Panayotes Demakakos

Nicola J Shelton

Affiliations

Soon will be listed here.

Abstract

Background: The extent that controlled diabetes impacts upon mortality, compared with uncontrolled diabetes, and how pre-diabetes alters mortality risk remain issues requiring clarification.

Methods: We carried out a cohort study of 22,106 Health Survey for England participants with a HbA1C measurement linked with UK mortality records. We estimated hazard ratios (HRs) of all-cause, cancer and cardiovascular disease (CVD) mortality and 95% confidence intervals (CI) using Cox regression.

Results: Average follow-up time was seven years and there were 1,509 deaths within the sample. Compared with the non-diabetic and normoglycaemic group (HbA1C <5.7% [<39 mmol/mol] and did not indicate diabetes), undiagnosed diabetes (HbA1C ≥6.5% [≥48 mmol/mol] and did not indicate diabetes) inferred an increased risk of mortality for all-causes (HR 1.40, 1.09-1.80) and CVD (1.99, 1.35-2.94), as did uncontrolled diabetes (diagnosed diabetes and HbA1C ≥6.5% [≥48 mmol/mol]) and diabetes with moderately raised HbA1C (diagnosed diabetes and HbA1C 5.7-<6.5% [39-<48 mmol/mol]). Those with controlled diabetes (diagnosed diabetes and HbA<5.7% [<39 mmol/mol]) had an increased HR in relation to mortality from CVD only. Pre-diabetes (those who did not indicate diagnosed diabetes and HbA1C 5.7-<6.5% [39-<48 mmol/mol]) was not associated with increased mortality, and raised HbA1C did not appear to have a statistically significant impact upon cancer mortality. Adjustment for BMI and socioeconomic status had a limited impact upon our results. We also found women had a higher all-cause and CVD mortality risk compared with men.

Conclusions: We found higher rates of all-cause and CVD mortality among those with raised HbA1C, but not for those with pre-diabetes, compared with those without diabetes. This excess differed by sex and diabetes status. The large number of deaths from cancer and CVD globally suggests that controlling blood glucose levels and policies to prevent hyperglycaemia should be considered public health priorities.

Citing Articles

NT-proBNP and cardiovascular event risk in individuals with prediabetes undergoing cardiovascular evaluation.

Witkowski M, Wu Y, Tang W, Hazen S Diabetes Res Clin Pract. 2023; 205:110923.

PMID: 37774978 PMC: 10843144. DOI: 10.1016/j.diabres.2023.110923.

Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes.

Witkowski M, Wu Y, Hazen S, Tang W Cardiovasc Diabetol. 2021; 20(1):171.

PMID: 34419046 PMC: 8379781. DOI: 10.1186/s12933-021-01365-9.

Mortality risk in adults according to categories of impaired glucose metabolism after 18 years of follow-up in the North of Spain: The Asturias Study.

Ares J, Valdes S, Botas P, Sanchez-Ragnarsson C, Rodriguez-Rodero S, Morales-Sanchez P PLoS One. 2019; 14(1):e0211070.

PMID: 30703129 PMC: 6354980. DOI: 10.1371/journal.pone.0211070.

Cancer incidence among Finnish people with type 2 diabetes during 1989-2014.

Saarela K, Tuomilehto J, Sund R, Keskimaki I, Hartikainen S, Pukkala E Eur J Epidemiol. 2018; 34(3):259-265.

PMID: 30182324 DOI: 10.1007/s10654-018-0438-0.

Comparison of surveillance-based metrics for the assessment and monitoring of disease detection: simulation study about type 2 diabetes.

Brinks R, Hoyer A, Rolka D, Kuss O, Gregg E BMC Med Res Methodol. 2017; 17(1):54.

PMID: 28399821 PMC: 5387346. DOI: 10.1186/s12874-017-0328-2.

References

Andersson C, Van Gaal L, Caterson I, Weeke P, James W, Coutinho W . Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 2012; 55(9):2348-55. DOI: 10.1007/s00125-012-2584-3. View

Mindell J, Biddulph J, Hirani V, Stamatakis E, Craig R, Nunn S . Cohort profile: the health survey for England. Int J Epidemiol. 2012; 41(6):1585-93. DOI: 10.1093/ije/dyr199. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Sluik D, Boeing H, Montonen J, Kaaks R, Lukanova A, Sandbaek A . HbA1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitus. PLoS One. 2012; 7(6):e38877. PMC: 3374773. DOI: 10.1371/journal.pone.0038877. View

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

Xu L, Chan W, Hui Y, Lam T . Association between HbA1c and cardiovascular disease mortality in older Hong Kong Chinese with diabetes. Diabet Med. 2011; 29(3):393-8. DOI: 10.1111/j.1464-5491.2011.03456.x. View

de Beer J, Liebenberg L . Does cancer risk increase with HbA1c, independent of diabetes?. Br J Cancer. 2014; 110(9):2361-8. PMC: 4007234. DOI: 10.1038/bjc.2014.150. View

Yu H, Spitz M, Mistry J, Gu J, Hong W, Wu X . Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999; 91(2):151-6. DOI: 10.1093/jnci/91.2.151. View

Jee S, Ohrr H, Sull J, Yun J, Ji M, Samet J . Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293(2):194-202. DOI: 10.1001/jama.293.2.194. View

10.

Elley C, Kenealy T, Robinson E, Drury P . Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med. 2008; 25(11):1295-301. DOI: 10.1111/j.1464-5491.2008.02581.x. View

11.

Monami M, Vitale V, Lamanna C, Bartoli N, Martelli D, Zannoni S . HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for personalised therapeutic targets. Nutr Metab Cardiovasc Dis. 2012; 23(4):300-6. DOI: 10.1016/j.numecd.2012.01.003. View

12.

Joshu C, Prizment A, Dluzniewski P, Menke A, Folsom A, Coresh J . Glycated hemoglobin and cancer incidence and mortality in the Atherosclerosis in Communities (ARIC) Study, 1990-2006. Int J Cancer. 2011; 131(7):1667-77. PMC: 3906204. DOI: 10.1002/ijc.27394. View

13.

Bao C, Yang X, Xu W, Luo H, Xu Z, Su C . Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J Diabetes Complications. 2013; 27(4):357-64. DOI: 10.1016/j.jdiacomp.2013.01.004. View

14.

Farmer A . Use of HbA1c in the diagnosis of diabetes. BMJ. 2012; 345:e7293. DOI: 10.1136/bmj.e7293. View

15.

Skriver M, Stovring H, Kristensen J, Charles M, Sandbaek A . Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study. Diabetologia. 2012; 55(9):2361-70. DOI: 10.1007/s00125-012-2614-1. View

16.

Saydah S, Lochner K . Socioeconomic status and risk of diabetes-related mortality in the U.S. Public Health Rep. 2010; 125(3):377-88. PMC: 2848262. DOI: 10.1177/003335491012500306. View

17.

Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A . Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014; (2):CD009122. PMC: 6486147. DOI: 10.1002/14651858.CD009122.pub2. View

18.

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

19.

. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7):1327-34. PMC: 2699715. DOI: 10.2337/dc09-9033. View

20.

Sakurai M, Saitoh S, Miura K, Nakagawa H, Ohnishi H, Akasaka H . HbA1c and the risks for all-cause and cardiovascular mortality in the general Japanese population: NIPPON DATA90. Diabetes Care. 2013; 36(11):3759-65. PMC: 3816883. DOI: 10.2337/dc12-2412. View